Taisho Pharmaceutical (TAIPY) Stock Price, News & Analysis

Company Overview

Taisho Pharmaceutical Co., Ltd. traces its roots back to 1912 when it was established in Tokyo, Japan, as Taisho Seiyaku. Over more than a century of operations, the company has expanded from a domestic producer of proprietary medicines into a diversified healthcare group. Today, Taisho Pharmaceutical operates across multiple segments, including ethical pharmaceuticals, over‐the‐counter (OTC) drugs, quasi‐drugs and health‐oriented products, while continuing to uphold its founding commitment to innovation and quality.

In the ethical pharmaceuticals segment, Taisho develops and markets prescription medicines addressing areas such as oncology, central nervous system disorders and gastrointestinal health. The company has built a global R&D network and has in-licensed novel candidates to strengthen its pipeline, notably in lung cancer and rare diseases. In parallel, its OTC portfolio features household names such as Pabron brand cold remedies and Loxonin analgesics, alongside digestive care and nutritional supplements. Taisho also offers cosmetic and quasi‐drug products, further broadening its consumer health footprint.

Taisho Pharmaceutical maintains a robust international presence, with operations spanning Asia, North America and Europe. The company leverages subsidiary offices, joint ventures and strategic partnerships to distribute its products in over 80 countries. In key markets such as China and Southeast Asia, Taisho focuses on localized manufacturing and marketing, while in the United States and Europe it emphasizes collaborations with specialty distributors and biotech firms to introduce advanced therapies and bolster its global supply chain resilience.

Under the leadership of President and CEO Kiyoshi Yonekawa, Taisho Pharmaceutical has implemented a midterm management plan that prioritizes sustainable growth, digital transformation and patient-centric innovation. The company continues to invest in R&D facilities and alliances with academic institutions and industry partners to accelerate the discovery of new treatment modalities. As it moves forward, Taisho remains committed to enhancing its portfolio, strengthening global networks and delivering value to patients, healthcare providers and shareholders alike.

Key Stats

• Today's Range: $14.00 to $14.00
• 50-Day Range: $14.00 to $14.00
• 52-Week Range: $8.88 to $15.52
• Volume: N/A
• Average Volume: 1,958 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TAIPY Stock Analysis - Frequently Asked Questions

How have TAIPY shares performed this year?

Taisho Pharmaceutical's stock was trading at $14.00 on January 1st, 2025. Since then, TAIPY stock has increased by 0.0% and is now trading at $14.00.

How do I buy shares of Taisho Pharmaceutical?

Shares of TAIPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TAIPY
• CIK: 1716957
• Web: www.taisho-holdings.co.jp
• Phone: (133) 985-2020
• Fax: N/A
• Employees: 8,784
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A